Resiquimod

Drug Profile

Resiquimod

Alternative Names: R 848; S 28463; VML 600

Latest Information Update: 21 Dec 2015

Price : $50

At a glance

  • Originator 3M Pharmaceuticals
  • Developer Spirig Pharma
  • Class Adjuvants; Antineoplastics; Antivirals; Imidazoles; Skin disorder therapies; Small molecules
  • Mechanism of Action Immunostimulants; Interferon alpha stimulants; Toll-like receptor 7 agonists; Toll-like receptor 8 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Actinic keratosis; Basal cell cancer; Hepatitis C; Herpes simplex virus infections; Immunological disorders

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 24 Oct 2013 Spirig Pharma discontinues a phase II trial in Basal cell carcinoma in Germany (NCT01808950)
  • 04 Sep 2013 Spirig Pharma discontinues a phase II trial in Actinic keratosis in Germany and Switzerland (NCT01806961)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top